The Belfer Institute for Applied Cancer Science is accelerating cancer drug discovery through identification of novel targets via cutting-edge approaches, applying and evolving predictive oncology models, and integrating understanding of clinical response into drug discovery efforts. We are driven by our pursuit of translating world-class scientific discoveries into therapeutic results to significantly impact the lives of cancer patients.
In the News
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.
Oral presentation, Serial monitoring of EGFR mutations in plasma NSCLC patients by ddPCR, at the 2014 AACR General Meeting in San Diego by Cloud Paweletz PhD, Head of Translational Research Lab.
Findings from the Translational Research Lab within the Belfer Institute demonstrate that circulating DNA from non-invasive plasma samples is a promising biomarker to monitor response and predict resistance in the clinic.
Belfer scientists collaborate with W. Kaelin MD , to demonstrate that the Ikaros family of transcription factors are key downstream mediators of the efficacy of thalidomide-like drugs.